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Abstract
Increased plasma levels of cholesterol are high risk factors of cardiovascular disease. Statins are drugs that inhibit 
cholesterol synthesis at both pancreatic and extrahepathic levels, being the treatment of choice for hypercholestero-
lemia.
Objective: To analyze the side effects of statins in the mouth cavity, and to analyze the symptoms after interruption 
of the treatment.
Design: Observational study, preliminary.
Material and methods: Patients aged 50-70, diagnosed with hypercholesterolemia and undergoing treatment with 
statins, referred from their primary care physician to the dentist’s office. Anamnesis over oral symptoms was perfor-
med in the first visit. Statin treatment was discontinued, followed by lab tests and control visits seven and fifteen days 
later. We monitored the improvement and/or remission of oral symptoms. Statin treatment was resumed, sending 
out a report of the patient evolution to the PCP. Symptoms were registered in sheet specially designed for the study. 
Exclusion criteria: patient refusal, use of drugs for dry mouth treatment, Sjögren’s syndrome.
Results: n=26 patients. Dry mouth patients: improvement in 17 out of 23 patients (88.5%). Itchiness: 6 out of 15 
cases improved (57.7%). Bitterness: improvement in 13 out of 14 patients (53.8%). Cough: improvement in 11 out 
of 12 patients (46.1%).
Discussion: A high percentage of oral symptoms are associated to treatment with statins. There is a marked improve-
ment after temporary interruption of the treatment. Little is known regarding the side effects of oral treatment with 
statins.  This preliminary study includes a relatively small number of patients. The design of experimental treatments 
will be required to establish a true correlation between statin treatment and oral symptoms.
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Introduction
Dislipemia is an alteration of the lipid metabolism that is 
characterized by the increase of one or more lipid fractions 
in blood plasma.
The two main circulating lipids are triglycerides and cho-
lesterol, which are obtained by ingestion or endogenous 
synthesis in the liver. Their ingestion is an essential com-
ponent of a normal diet, because of their energy content 
and their role in organ and tissue structural support, as 
well as synthesis of hormones and neurotransmitters (1). 
Plasma lipids are associated to protein particles, forming 
lipoproteins. Lipoproteins obtained via intestinal absorp-
tion move in structures called chylomicrons. Chylomicrons 
bound to lipoproteins of  very low molecular density 
(VLDL) deposit lipids or fat on the adipose and muscular 
tissue, releasing fatty acids used for storage and energy 
transformation.
Simultaneous to the process of  intestinal absorption, 
intestinal cells synthesize lipid structures of different den-
sities. Depending on their composition, these particles are 
VLDL (very low density lipoprotein), LDL (low density 
lipoprotein) and HDL (high density lipoprotein).
LDL particles carry cholesterol to the tissues; when choles-
terol levels in blood are high, there is risk of cardiovascular 
disease (ischemic cardiopathy, vascular brain damage or 
peripheral vascular disease).  On the other hand, HDL 
particles transport cholesterol to the liver; this is conside-
red a protective factor in cardiovascular disease. 
The main types of dislipemia are:
-Hypertriglyceridemia: increase in plasmatic triglyceri-
des.  
-Hypercholesterolemia: increase in plasmatic choleste-
rol.  
-Mixed dislipemia: increase in triglycerides and plasmatic 
cholesterol.
The different types of dislipemia can be classified regar-
ding their ethiology:
-Primary: due to an alteration of lipid metabolism; they 
can be hereditary.
-Secondary: they are due to illness or drug use, e.g. diabetes 
mellitus, hypothyroid syndrome, alcoholism, treatment 
with ß-adrenergic blockers, etc.
The term dislipemia is used when total cholesterol in blood 
is over 200 mg/dl and triglycerides are over 160 mg/dl.
The prevalence of hypercholesterolemia in Spain varies 
among regions. It is estimated between 14% and 20% of 
adult population ages 18-75. Depending on the source, 
pathological levels are considered when cholesterol is 
over 200 or 250 mg/dl (1-8); there are 5-6 million cases 
in Spain (5). 
Hypercholesterolemia can be regarded as high among 
the population of Spain. 18% people aged 35-64 (18.6% 
men, 17.6 % women) have blood cholesterol levels equal 
or over 250 mg/dl, and 57.8% (56.7% men and 58.6 % 
women) equal or over 200 mg/dl (4). In women, cholesterol 
levels in blood correlate with age; however, that does not 
happen in men (4).
Strikingly, between 12 and 15 million dislipemia patients in 
the USA are undergoing treatment with statins, and there 
will be another 35 million in the near future (3). 
Dislipemia treatment
Healthy life style
Dislipemia treatment is based in the acquisition of  a 
healthy life style, which is targeted towards the reduction 
of cardiovascular disease.  These are some of the habits:
- Quit smoking.
- Reduce alcohol uptake to less than 30 g/day for men and 
20 g/day for women. It must be totally avoided in cases of 
hypertriglyceridemia.
- Keep an appropriate weight. Hypocaloric diet will be 
recommended for weight excess, and the progressive reduc-
tion of fat and cholesterol to less than 300 g per day.
- Appropriate aerobic exercise adapted to the needs of the 
patient (e.g. walking at least 30 minutes every day).
- Fat-reduced diet.
If  the dislipemia persists after a period between 3 and 
6 months following these guidelines, pharmacological 
treatment is required (2).
Pharmacological treatment 
Statins: The mechanism of action of statins consists of 
the inhibition of cholesterol synthesis in both the liver and 
extrahepatic tissue, therefore decreasing total cholesterol 
(TC) and cLDL (6). They are less potent on cVLDL levels 
and triglycerides (TG). They can induce modest increases 
of cHDL levels.
A non-comprehensive list of available statins (by order of 
appearance in the market) includes lovastatin, simvastatin, 
pravastatin, fluvastatin and atorvastatin. Their pharma-
cological effect is dose-dependent, reaching a plateau at 
high doses. Statins are prescribed one dose/ day, and taken 
at night, because maximal cholesterol synthesis occurs in 
the AM. In conclusion, this is the treatment of choice in 
the treatment of hypercholesterolemia (9).
Fibrates: They reduce the synthesis of  cholesterol and 
enhance its elimination in the bile. They increase the ca-
tabolism of TG (6), thus decreasing their levels, and also 
increase cHDL. They show lower efficacy on cholesterol 
and cLDL than statins.  They are useful in mixed dislipe-
mia, in which hypertriglyceridemia is dominant.
Resins: They interfere with the absorption of bile acids 
in the intestine, increasing the conversion from hepatic 
cholesterol to fat (2). They diminish the levels of cLDL 
(to a lower extent than statins), but they can increase the 
levels of TG.  They do not constitute a treatment of choice 
in dislipemia.
Ezetimibe (2,6): It selectively blocks cholesterol absorption 
and vegetable sterols in the jejunum. It does not affect the 
absorption of TG or liposoluble vitamins. It also induces 
an average 15% decrease in cLDL levels in monotherapy, 
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and combination with statins further decreases them an 
additional 15-20%. To our knowledge, there are no publis-
hed studies on its effect on cardiovascular-related mortali-
ty, and its safety is unknown in short- and long-term.
Adverse effects of statins
Statins induce an average 26% reduction of the risk of 
cardiovascular disease (angina, stroke, ictus, etc.), but 
they are also related to severe adverse effects (AE). To our 
knowledge, no studies have addressed the oral AE of sta-
tins despite of the abundance of references in the literature 
about other statin-induced AE (Medline, Cochrane).
Silva et al. described that in 1000 patients following statin 
treatment, 37% did not exhibit any detectable cardiovas-
cular pathology, but 5% had somatic AE (3).
Rhabdomyolisis is the most severe AE of statin treatment, 
but also the less frequent. An increase in creatine phospho-
kinase (CPK), up to 10 times higher than normal, has been 
reported. Less severe AE, such as myalgia and increased 
hepatic transaminases levels comprise about two thirds 
of AE reported in this study, but these symptoms receded 
after discontinuation of the treatment (3).
According to Hioriuchi et al. (10), statins seem to poten-
tially stimulate bone formation in vitro. Statin treatment, 
in combination with traditional drugs for osteoporosis 
treatment, such as 17-estradiol, increases bone formation 
in the jaw, especially in the alveolar bone. This suggests 
amelioration of periodontal disease in osteoporosis pa-
tients, concurrent with decreased breakdown (10).
The frequency and severity of AE due to statin treatment 
is related to their own potency. Atorvastatin is the most 
potent (per mg of active principle), therefore the most 
typically associated with unwanted AE. Fluvastatine ex-
hibits the lowest efficacy, which correlates with less AE. 
Simvastatin, pravastatin and lovastatin pose intermediate 
risk of AE.
Our work at the Odontology Service of Primary Atten-
tion of Basic Health Area (BHA) Sant Roc (Badalona) 
has revealed different oral AE, based on spontaneous 
accounts by most of the patients complaining about dis-
comfort and malcontent. Reported AE include dry mouth 
and throat (sometimes accompanied by cough), and a 
constant need for water; bitterness, parestesia, tongue 
itchiness (tip and/or sides) and the vestibular portion of 
the lips; insomnia. 
Working hypothesis
Hypolipemia treatment with statins could be the cause of 
diverse oral pathologies. 
Aims
General aim: To evaluate if statin uptake causes side effects 
in the oral cavity.
Specific aims: 1) to describe and quantify the traits of 
such adverse effects; 2) to evaluate its evolution after 
discontinuation of the treatment.
Material and Methods
We performed a preliminary observational study of 
patients from the BHA Sant Roc (Badalona). Inclu-
sion criteria were: patients aged 50-70, diagnosed with 
hypercholesterolemia (cholesterol over 200 mg/dl), un-
dergoing treatment with statins. Exclusion criteria were: 
patients diagnosed with Sjögren syndrome, or following 
treatment with drugs producing dry mouth as side effect 
(e.g. drugs with anticholinergic activity, benzodiazepines, 
and diuretics; patients diagnosed with chronic obstructive 
pulmonary disease or chronic bronchitis). In agreement 
with these criteria, 28 patients were included in the study. 
Two of them presented severe cough, itchiness and dry-
ness, and declined further participation; thus, 26 patients 
completed the study.
Patients were recruited randomly at the Primary Care 
Centre offices of the BHA for a month. The patients were 
first informed of the purpose of the study, and upon com-
pliance with the inclusion criteria, they were transferred 
to the dentist office for revision and further participation 
in the study.
Each participant was examined twice. Personal and clini-
cal data were collected during the first visit.  Anamnesis 
was directed to the discomfort in the oral cavity: dryness, 
itchiness/parestesia, bitterness and cough; the patients 
were questioned about insomnia and other symptoms 
on their own account. Laboratory tests were conducted, 
including a basic health revision, liver blood markers, lipid 
levels, CPK, alkaline phosphatases and bilirubine. Statin 
treatment was then discontinued for two weeks; this time 
was selected to grant metabolic elimination of the drug 
and allow the onset of changes related to the interruption 
of the treatment.
We then monitored the patient’s response in the second 
visit. These responses were graded according to an impro-
vement index (II), defined as an observable decrease of 
any symptom; and a recovery index (RI), defined as the 
absence of each and every symptom.          
Results of the study
The distribution of AE observed in our study was: dry 
mouth (23 patients), itchiness/parestesia in tongue, lips 
and throat (15 patients), bitterness (14 patients), cough (12 
patients) and insomnia (related to previous symptoms). 
The distribution by type of statin administered was: simvas-
tatin (n=15), pravastatin (n=7), atorvastatin (n=3), and 
lovastatin (n=1).
Among the 23 patients presenting dryness, 17 showed 
improvement over the course of the study (Improvement 
Index [II]=73.91%). Regarding bitterness, 13 patients 
out of 14 reported complete remission (Recovery Index 
[RI]=92.86%). 11 of 12 patients presenting cough impro-
ved after discontinuation of the treatment (II=91.67%). 
Finally, out of 15 patients showing itchiness in tongue, 
lips and throat, 7 suffering from tongue itchiness exhibited 
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total remission (RI=46.67%) and 3 more improved signifi-
cantly. Another 3 patients suffering from throat itchiness 
also improved (II=40%) (Table 1).
16 out of 17 patients presenting insomnia improved after 
interruption of the treatment (II=94.12%).
Regarding the analytical AE, CPK levels were normal; 
only 2 patients presented a slight increase, but they never 
were over tenfold the normal levels.                                                          
Discussion
In this study, we have observed a high percentage of oral 
symptoms in patients undergoing treatment with statins; 
to our knowledge, this is the first report of such adverse 
effects despite the numerous papers addressing the various 
side effects of this type of treatment. 
On the other hand, we have observed that the AE disappea-
red in a high percentage of patients after suspension of 
the treatment, and improvement was observed as early as 
the third day after interruption.
Dryness improved or remitted in 73.9% of the patients; 
this is a high percentage considering the average age of 
the patients and the fact that some of them presented 
pathologies that induce xerostomy. Similar results were 
observed regarding cough (91.7%); after dryness improved, 
nocturnal cough episodes also improved.
Bitterness (92.8%) and itchiness in tongue and lips (86.7%) 
improved or disappeared in all patients exhibiting those 
symptoms.
 94 % of patients with insomnia reported better rest after 
interruption of the treatment. When the treatment was 
resumed, administration was shifted to the morning time 
despite the pharmacokinetic characteristics of the drugs. 
This change resulted in improvement of the symptoms 
and hours of sleep.
In summary, this study reveals a frequent association bet-
ween oral symptoms and treatment with statins. The fact 
that there is an important improvement after interruption 
of the treatment suggests that these symptoms could be a 
side effect to the treatment. However, these results must 
be considered carefully, and further studies including 
more patients are necessary to establish their reliability. 
This will require the joint collaboration of  dentists to 
determine the AE of statins related to the oral cavity and 
PCPs to consider alternatives treatment for patients with 
high risk of cardiovascular disease when the adverse effects 
are too severe.
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Table 1. Oral symptoms and evolution after interruption of the treatment with statins.
